Alpha Cognition Inc (ACOG)vsJohnson & Johnson (JNJ)
ACOG
Alpha Cognition Inc
$8.74
-4.90%
HEALTHCARE · Cap: $190.34M
JNJ
Johnson & Johnson
$273.20
-0.73%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 650820% more annual revenue ($99.33B vs $15.26M). JNJ leads profitability with a 16.2% profit margin vs -137.7%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ACOG
Avoid28
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACOG.
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$273.20
$129.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 267.6% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -43.8% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Revenue Growth. Revenue growth of 267.6% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : ACOG
The primary concerns for ACOG are EPS Growth, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ACOG profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.23 — expect wider price swings.
ACOG is growing revenue faster at 267.6% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 28/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's flagship candidate, ACOG-100, seeks to improve cognitive function and tackle significant unmet needs among the aging demographic. With a robust proprietary neuroscience platform and a deep commitment to rigorous research and development, Alpha Cognition is well-positioned for growth as it advances its clinical pipeline and explores new therapeutic avenues. For institutional investors, the company presents a compelling opportunity to contribute to transformative patient care while capitalizing on the expanding healthcare sector.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?